Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$KIN https://zimeta.com/about-fever-in-horses/
About Fever in Horses
Reasons why horses may experience elevated body temperature
In horses, elevated core body temperature (greater than 101.5°F) is the result of either hyperthermia or pyrexia (fever). Hyperthermia conditions include exercise-related hyperthermia, heat stroke, and reactions to certain toxins or drugs. In general, these conditions do not respond to antipyretic drugs.1
In a true fever, the set point for the physiologic core body temperature increases as a response to infection or inflammation. Although there are documented benefits of fever in many disease processes, managing fever also has benefits, particularly in the horse.1
Fever takes valuable energy
Nutrition is an important part of managing and treating sick horses. Fever increases caloric needs of horses, and inadequate nutrition may result in impaired immune system function, delayed wound or fracture healing, and/or muscle wasting.2
Fever can have serious secondary effects
Managing fever in a sick horse is important to help offset potential negative sequelae, including weakness, muscle wasting, and weight loss.1
Well-documented secondary effects of fever can include anorexia and decreased water intake, which may be associated with gastrointestinal impactions.1,3,4,5
Common causes of fever in horses
Fever is a clinical sign commonly associated with various underlying infectious and non-infectious diseases in the horse. Transportation of horses often results in fever, with incidence increasing with greater travel time and distances. One study showed fever occurred in 47.2% of clinically normal horses with no prior history of respiratory disease following transport.6
Diseases that may present with fever as a clinical sign include:
• Pneumonia/Pleuropneumonia7
• Acute diarrhea8
• Duodenitis/Proximal jejunitis8
• Internal infections10
These diseases are often associated with endotoxemia, a risk factor for sequelae including alminitis.11
$KIN Relieve Pyrexia at the source with Zimeta The first and only drug FDA-approved for control of pyrexia in horses1
[-chart]live-zimeta.pantheonsite.io/wp-content/uploads/2020/05/zimetalogo.png[/chart]
[-chart]zimeta.com/wp-content/uploads/2020/06/zimeta-product-shot-1.jpg[/chart]
https://zimeta.com/
$KIN MISCELLANEOUS Employees146 Outstanding Shares39,290,000
Market Cap$131.62 million
Next Earnings Date8/5/2020 (Confirmed)
OptionableOptionable
$KIN SALES & BOOK VALUE Book Value$2.10 per share Price / Book1.60
Annual Sales$4.26 million
Price / Sales30.90
Cash FlowN/A
Price / Cash FlowN/A
Book Value$2.10 per share
Price / Book1.60
$KIN 07-29-2020 btm.Kindred Biosciences Announces COVID-19 Vaccine Manufacturing Agreement with Vaxart
May 20, 2020
San Francisco, California (May 20, 2020) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company developing novel biologics,
today announced it has entered into an agreement with Vaxart, Inc. (Nasdaq: VXRT) for the manufacture of Vaxart’s oral vaccine candidate for COVID-19.
“We are proud to be contributing toward the effort to develop a COVID-19 vaccine.
We look forward to working with Vaxart to bring this innovative technology to patients as quickly as possible,” said KindredBio’s Chief Executive Officer,
Richard Chin, M.D.
“This marks an important step in the development of our contract manufacturing business, which has the potential to help fund our promising pipeline.”
Under the terms of the agreement, KindredBio will provide manufacturing services from its state-of-the-art biological development and cGMP manufacturing facility in Burlingame, CA.
There, KindredBio will produce the candidate vaccine bulk drug substance under Good Manufacturing Practices,
and provide it to Vaxart to be
formulated into a vaccine tablet to be taken by mouth
instead of by needle injection.
KindredBio will manufacture the vaccine for clinical trials beginning in the second half of 2020.
“We are pleased to be partnering with Kindred Biosciences in the development of our oral COVID-19 vaccine candidate,” said Vaxart’s Chief Executive Officer,
Wouter Latour, M.D.
“We believe our novel approach utilizing a room temperature-stable tablet offers important logistical advantages in widespread oral vaccination,
and that KindredBio with its state-of-the-art manufacturing plants is
an ideal partner to realize our vision.”
KindredBio’s core expertise includes protein engineering,
cell line development,
master cell banking, process development, assay development, stability testing, and
cGMP clinical and
commercial manufacturing from 50 litres to 2,000 litres.
The biologics team comprises experts in product development, manufacturing,
quality control and quality assurance personnel,
and is supported by a strong project management organization.
KindredBio’s contract development and manufacturing (CDMO) activities are managed by a wholly owned subsidiary,
Centaur Biopharmaceutical Services.
About Kindred Biosciences
Kindred Biosciences is a biopharmaceutical company developing innovative biologics focused on saving and improving the lives of pets.
Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy.
The company’s strategy is to identify targets that have already demonstrated safety and efficacy in
humans and to develop therapeutics based on these validated targets for dogs and cats.
KindredBio has a deep pipeline of novel biologics in development across many therapeutic classes,
alongside state-of-the-art biologics manufacturing capabilities and a broad intellectual property portfolio.
For more information, please visit: Http://www.kindredbio.com
About Vaxart
Vaxart is a clinical-stage biotechnology company and its oral recombinant vaccine candidate is based on its proprietary VAAST™ platform. Vaxart’s vaccines are administered using a convenient room temperature-stable tablet, rather than by injection.
For more information, please visit http://www.vaxart.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding our expectations about the trials, regulatory approval, manufacturing, distribution and commercialization of our current and future product candidates, and statements regarding our anticipated revenues, expenses, margins, profits and use of cash.
These forward-looking statements are based on our current expectations. These statements are not promises or guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results to be materially different from any future results expressed or implied by the forward-looking statements. These risks include, but are not limited to, the following: our limited operating history and expectations of losses for the foreseeable future; the absence of significant revenue from our products and our product candidates for the foreseeable future; the likelihood that our revenue will vary from quarter to quarter; our potential inability to obtain any necessary additional financing; our substantial dependence on the success of our products and our lead product candidates which may not be successfully commercialized even if they are approved for marketing; the effect of competition; our potential inability to obtain regulatory approval for our existing or future product candidates; our dependence on third parties to conduct some of our development activities; our dependence upon third-party manufacturers for supplies of our products and our product candidates and the potential inability of these manufacturers to deliver a sufficient amount of supplies on a timely basis; the uncertain effect of the COVID-19 pandemic on our business, results of operations and financial condition; uncertainties regarding the outcomes of trials regarding our product candidates; our potential failure to attract and retain senior management and key scientific personnel; uncertainty about our ability to enter into satisfactory agreements with third-party licensees of our biologic products or to develop a satisfactory sales organization for our equine small molecule products; our significant costs of operating as a public company; potential cyber-attacks on our information technology systems or on our third-party providers’ information technology systems, which could disrupt our operations; our potential inability to repay the secured indebtedness that we have incurred from third-party lenders, and the restrictions on our business activities that are contained in our loan agreement with these lenders; the risk that our 2020 strategic realignment plan will result in unanticipated costs or revenue shortfalls; uncertainty about the amount of royalties that we will receive from the sale of Mirataz® to Dechra Pharmaceuticals PLC; our potential inability to obtain and maintain patent protection and other intellectual property protection for our products and our product candidates; potential claims by third parties alleging our infringement of their patents and other intellectual property rights; our potential failure to comply with regulatory requirements, which are subject to change on an ongoing basis; the potential volatility of our stock price; and the significant control over our business by our principal stockholders and management.
For a further description of these risks and other risks that we face, please see the risk factors described in our filings with the U.S. Securities and Exchange Commission (the SEC), including the risk factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K and any subsequent updates that may be contained in our Quarterly Reports on Form 10-Q filed with the SEC. As a result of the risks described above and in our filings with the SEC, actual results may differ materially from those indicated by the forward-looking statements made in this press release. Forward-looking statements contained in this press release speak only as of the date of this press release and we undertake no obligation to update or revise these statements, except as may be required by law.
The results stated in this press release have not been reviewed by the Food and Drug Administration or the United States Department of Agriculture Center for Veterinary Biologics, as applicable.
Contacts
For investor inquiries:
Katja Buhrer
Katja.buhrer@kindredbio.com
(917) 969-3438
For CDMO services:
Jeremy Vrchota
jeremy.vrchota@kindredbio.com
(605) 370-2258
Share this entry
$KIN THIS DREW ME HERE PARTNERSHIP WIT VXRT !!!!!
$KIN BTM CALL TODAY MY FRIEND !!!!!
$KIN Kindred Biosciences (KIN)
3.355 ? -0.145 (-4.14%)
Volume: 243,056 @07/29/20 2:52:33 PM EDT
Bid Ask Day's Range
3.35 3.36 3.32 - 3.71
KIN Detailed Quote
$KIN BTM CALL
$KIN Kindred Biosciences (KIN)
3.88 ? -0.15 (-3.72%)
Volume: 115,338 @07/24/20 4:09:06 PM EDT
Bid Ask Day's Range
3.86 4.33 3.856 - 4.03
KIN Detailed Quote
$KIN 'Kindred Biosciences Inc (KIN)'
Kindred Biosciences (KIN)
4.13 ? -0.1 (-2.36%)
Volume: 4,074,716 @06/26/20 7:59:20 PM EDT
Bid Ask Day's Range
4.1 4.25 4.055 - 5.4344
KIN Detailed Quote
Kindred Biosciences (KIN)
4.34 ? -0.1 (-2.25%)
Volume: 283,139 @06/12/20 6:10:02 PM EDT
Bid Ask Day's Range
4.11 4.79 4.29 - 4.85
KIN Detailed Quote
$KIN NICE MOVE Kindred Biosciences (KIN)
5.22 ? 0.37 (7.63%)
Volume: 159,263 @06/10/20 1:24:24 PM EDT
Bid Ask Day's Range
5.2 5.22 4.81 - 5.22
KIN Detailed Quote
KIN hi mick
Kindred Biosciences (KIN)
4.7 ? -0.07 (-1.47%)
Volume: 491,793 @06/05/20 5:15:01 PM EDT
Bid Ask Day's Range
4.7 5.09 4.68 - 5.01
KIN Detailed Quote
$KIN, IS MAKING SOME HEADWAY !!!!!
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/22/2020 7:32:46 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/20/2020 8:02:31 AM
Kindred Biosciences Announces COVID-19 Vaccine Manufacturing Agreement with Vaxart PR Newswire (US) - 5/20/2020 7:58:00 AM
Kindred Biosciences to Present at Stifel 2020 Virtual Jaws & Paws Conference PR Newswire (US) - 5/13/2020 8:30:00 AM
Amended Securities Registration (section 12(b)) (8-a12b/a) Edgar (US Regulatory) - 5/12/2020 4:19:12 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/12/2020 4:12:27 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/7/2020 4:31:05 PM
C
Current Report Filing (8-k) Edgar (US Regulatory) - 5/7/2020 4:10:35 PM
Kindred Biosciences Announces First Quarter 2020 Financial Results PR Newswire (US) - 5/7/2020 4:02:00 PM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 4/29/2020 6:24:49 AM
Kindred Biosciences (KIN)
5.12 ? 0.59 (13.02%)
Volume: 611,372 @05/22/20 5:11:36 PM EDT
Bid Ask Day's Range
4.5 5.22 4.55 - 5.21
KIN Detailed Quote
News: $KIN Kindred Biosciences to Announce First Quarter 2019 Financial Results
SAN FRANCISCO , April 25, 2019 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced that it will release its first quarter 2019 financial results on May 9, 2019 ...
Got this from https://marketwirenews.com/news-releases/kindred-biosciences-to-announce-first-quarter-2019-financial-results-8057232.html
OK this is a Veterinarian biotech.
http://kindredbio.com/pipeline/
Any one in on this guy?? I bought a small amount of shares to test that waters. I think I like it, but looking for more DD.
Any one in on this guy?? I bought a small amount of shares to test that waters. I think I like it, but looking for more DD.
Any one in on this guy?? I bought a small amount of shares to test that waters. I think I like it, but looking for more DD.
Any one in on this guy?? I bought a small amount of shares to test that waters. I think I like it, but looking for more DD.
SEC APPROVES KIN REGISTRATION! http://ih.advfn.com/p.php?pid=nmona&article=65315477
took profits earlier today on this one. Now it is dropping off. Will watch to see where it finds bottom.
Come on baby, let's break out of this range to the upside :)
nice day shaping up here. Let's start moving now and close that gap. KIN
CC was very good and you can listen to it at the kindred biosciences website.
Because the IPO did so well they are going to add more targets.
Richard Chin the CEO and founder mentioned they have been contacted numerous times in regard to
"partnering" and that is an option they have if so needed.
They have enough cash for three years and by then they should be cash positive according to management.
Many catalysts to maintain momentum for years in my opinion and we all have an opportunity to get in early which I have of course. Cheers
Kindred still has plenty of upside from here due to numerous catalysts.
We should hear something regarding SentiKin this month.
Followers
|
4
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
144
|
Created
|
01/04/14
|
Type
|
Free
|
Moderators |
Kindred Biosciences Announces Plan to Strengthen its Strategic Position
June 8, 2020
SAN FRANCISCO , June 8, 2020 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: K...
Kindred Biosciences Announces COVID-19 Vaccine Manufacturing Agreement with Vaxart
May 20, 2020
SAN FRANCISCO , May 20, 2020 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: K...
May 13, 2020
SAN FRANCISCO , May 13, 2020 /PRNewswire/ -- Kindred Biosciences , Inc. (NASDAQ: ...
Kindred Biosciences Announces First Quarter 2020 Financial Results
May 7, 2020
SAN FRANCISCO , May 7, 2020 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: K...
Kindred Biosciences to Announce First Quarter 2020 Financial Results
April 23, 2020
Company to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time/1:30 p.m. P...
Kindred Biosciences Announces Completion of Mirataz® (mirtazapine transdermal ointment) Transaction
April 15, 2020
$KIN 07-29-2020 btm.Kindred Biosciences Announces COVID-19 Vaccine Manufacturing Agreement with Vaxart
May 20, 2020
San Francisco, California (May 20, 2020) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company developing novel biologics,
today announced it has entered into an agreement with Vaxart, Inc. (Nasdaq: VXRT) for the manufacture of Vaxart’s oral vaccine candidate for COVID-19.
“We are proud to be contributing toward the effort to develop a COVID-19 vaccine.
We look forward to working with Vaxart to bring this innovative technology to patients as quickly as possible,” said KindredBio’s Chief Executive Officer,
Richard Chin, M.D.
“This marks an important step in the development of our contract manufacturing business, which has the potential to help fund our promising pipeline.”
Under the terms of the agreement, KindredBio will provide manufacturing services from its state-of-the-art biological development and cGMP manufacturing facility in Burlingame, CA.
There, KindredBio will produce the candidate vaccine bulk drug substance under Good Manufacturing Practices,
and provide it to Vaxart to be
formulated into a vaccine tablet to be taken by mouth
instead of by needle injection.
KindredBio will manufacture the vaccine for clinical trials beginning in the second half of 2020.
“We are pleased to be partnering with Kindred Biosciences in the development of our oral COVID-19 vaccine candidate,” said Vaxart’s Chief Executive Officer,
Wouter Latour, M.D.
“We believe our novel approach utilizing a room temperature-stable tablet offers important logistical advantages in widespread oral vaccination,
and that KindredBio with its state-of-the-art manufacturing plants is
an ideal partner to realize our vision.”
KindredBio’s core expertise includes protein engineering,
cell line development,
master cell banking, process development, assay development, stability testing, and
cGMP clinical and
commercial manufacturing from 50 litres to 2,000 litres.
PER MGMT DAVE -
IH Geek [Dave] DISCLAIMER |
01-31-2021
DISCLAIMER: ONLY FOR MICK
https://investorshub.advfn.com/boards/profilea.aspx?user=1012
*The Board Monitor and herewithin , are not licensed brokers and assume NO responsibility for actions,
investments,decisions, or messages posted on this forum.
CONTENT ON THIS FORUM SHOULD NOT BE CONSIDERED ADVISORY NOR SOLICITATION
AUTHORS MAY HAVE BUYS OR SELLS WITH THE COMPANIES MENTIONED IN TRADING POSTERS SHOULD DUE DILIGENT BUYING OR SELLING.
ALL POSTING SHOULD BE CONSIDERED FOR INFORMATION ONLY. WE DO NOT RECOMMEND ANYONE BUY OR SELL ANY SECURITIES POSTED HEREWITHIN.
ANY trade entered into risks the possibility of losing the funds invested.
• There are no guarantees when buying or selling any security.Any
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |